AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACDC Metals Ltd

0.060

-0.009-13.04%

Volume:129.73K

Turnover:7.92K

Market Cap:4.50M

PE:-6.36

High:0.065

Open:0.065

Low:0.060

Close:0.069

52wk High:0.160

52wk Low:0.036

Shares:74.93M

Float Shares:40.29M

Volume Ratio:4.88

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.009

ROE:-6.71%

ROA:-2.92%

PB:0.44

PE(LYR):-6.36

Loading ...

Overview Company News Filings

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

Agree Realty (ADC): How New Financing and Upbeat Guidance Shape the Company's Value Proposition

Simply Wall St.

Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition

Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards

Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal

Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation

Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025

How Investors May Respond To InnoCare Pharma (SEHK:9969) Advancing Novel B7-H3 ADC and Next-Gen TRK Inhibitor

Simply Wall St.

LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Agree Realty (ADC): Examining Valuation After Recent 5% Share Price Rebound

Simply Wall St.

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

Biokin Pharmaceutical Gets Nod to Trial Tumor Drug

MT Newswires Live

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

Will Agree Realty's (ADC) Dividend Hike Reveal the Strength of Its Shareholder Strategy?

Simply Wall St.

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

Will Agree Realty’s (ADC) $1.5 Billion Investment Deepen Its Role as a Reliable Dividend Payer?

Simply Wall St.

Prabowo Arrives in Amsterdam, Rides Dutch Royal Family's Limousine

Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.06,"timestamp":1764911520000,"preClose":0.069,"halted":0,"volume":129731,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"Not Yet Opened","change":-0.009,"latestTime":"12-05 16:12:00 AEDT","open":0.065,"high":0.065,"low":0.06,"amount":7916,"amplitude":0.072464,"askPrice":0.065,"askSize":24612,"bidPrice":0.06,"bidSize":26616,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765148400000},"marketStatusCode":0,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.069,"openAndCloseTimeList":[[1764889200000,1764910800000]],"volumeRatio":4.878168909376725,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":4.878168909376725,"shares":74930755,"dividePrice":0,"high":0.065,"amplitude":0.072464,"preClose":0.069,"low":0.06,"week52Low":0.036,"pbRate":"0.44","psRate":"13.05","week52High":0.16,"institutionHeld":0,"latestPrice":0.06,"committee":0.039119,"eps":-0.00943,"divideRate":0,"volume":129731,"delay":0,"ttmEps":-0.00943,"open":0.065,"prevYearClose":0.055,"prevWeekClose":0.06,"prevMonthClose":0.068,"prevQuarterClose":0.065,"fiveDayClose":0.068,"twentyDayClose":0.066,"sixtyDayClose":0.066},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"other","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4181","LU2065731478.USD","ADC","CRS.AU","ADC.AU","IE0031619046.USD","BK7095","IE00B66KJ199.SGD","IND.AU","IE00B7SZL793.SGD","ORR.AU","PK","BK4080","LU0963586101.USD","BK4187","IND","ORR","IE00B19Z4B17.USD","CRS","BK4231","BK4218"],"gpt_icon":0},{"id":"2587951731","title":"Agree Realty (ADC): How New Financing and Upbeat Guidance Shape the Company's Value Proposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2587951731","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587951731?lang=en_us&edition=fundamental","pubTime":"2025-11-28 23:21","pubTimestamp":1764343291,"startTime":"0","endTime":"0","summary":"Agree Realty (ADC) just closed a $350 million unsecured term loan with a 5.5-year duration and an accordion feature that allows for further lender commitments. This signals both financial flexibility and strength and is catching the attention of investors seeking stable growth.\nSee our latest analysis for Agree Realty.\nThe new financing arrives alongside upbeat news: Agree Realty lifted its 2025 AFFO and investment guidance and continues to draw positive attention from both analysts and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-how-new-financing-and-upbeat-guidance-shape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-how-new-financing-and-upbeat-guidance-shape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC.AU","BK4231","BK4080","ADC","BK7095"],"gpt_icon":0},{"id":"2585216418","title":"Fosun International Honored as \"ESG Leading Enterprise\" by Bloomberg Businessweek/Chinese Edition","url":"https://stock-news.laohu8.com/highlight/detail?id=2585216418","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585216418?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:00","pubTimestamp":1763686800,"startTime":"0","endTime":"0","summary":"This year, 12 companies were honored as \"ESG Leading Enterprises\" in Category I - market capitalization over HKD12 billion, all of which are major Hong Konglisted companies, includingHenderson Land, Sun Hung Kai Properties, Towngas, Hutchmed, China Telecom, China Unicom, and Bank of China .Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a robust ESG governance management system, embedding sustainability principles into its operations over the years. It has actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented \"dual carbon\" goals, protected the rights and interests of employees to promote sustainable management and value creation.Fosun adheres to an innovation-driven strategy, and the anticancer drugs developed by its Health segment have widely benefited ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fosun-international-honored-as-esg-leading-enterprise-by-bloomberg-businessweekchinese-edition-302622019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK1230","BK7509","BK4231","5HG.SI","BFC.AU","BK6095","BK6509","BK7141","ADC","ADC.AU","BFC","BK4211","BK7505","ESG","BK4080","00656"],"gpt_icon":0},{"id":"2584243956","title":"Ajinomoto Bio-Pharma Services Wins \"Best ADC Preclinical Publication 2024\" Award for AJICAP® Technology at 2025 World ADC Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2584243956","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584243956?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:26","pubTimestamp":1763389560,"startTime":"0","endTime":"0","summary":"Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies. TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services , a leading provider of biopharmaceutical contract development and manufacturing services,today announced it has been named the winner of the \"Best ADC Preclinical Publication 2024\" at the 12th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP linker technology.About Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and United States, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including high potenc","market":"sg","thumbnail":"https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ajinomoto-bio-pharma-services-wins-best-adc-preclinical-publication-2024-award-for-ajicap-technology-at-2025-world-adc-awards-302617219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK4231","BK4080","ADC","ADC.AU"],"gpt_icon":0},{"id":"2583541846","title":"Fosun International Receives \"ESG & Corporate Sustainability Excellence Award\" from Hong Kong Economic Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541846","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583541846?lang=en_us&edition=fundamental","pubTime":"2025-11-14 09:00","pubTimestamp":1763082000,"startTime":"0","endTime":"0","summary":"HKEJ noted that, in recent years, an increasing number of companies have been deeply integrating the concept of sustainability into their long-term investment strategies and business decision-making processes. International institutional investors also view ESG performance as a key indicator for assessing a company's long-term value. Studies have shown that advancing sustainability not only supports market expansion and strengthens risk management, but also enhances capital returns and overall financial performance. Against the backdrop of a rapidly evolving global business landscape, ESG has become an essential strategy for enterprises to maintain their competitive edge and achieve steady growth.Fosun has established a top-down and long-term mechanism for ESG improvement and has included ESG management performance as an evaluation factor in the Executive Directors' performance assessment, and the ESG management performance appraisal mechanism is also extended to the CEOs of the Group ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fosun-international-receives-esg--corporate-sustainability-excellence-award-from-hong-kong-economic-journal-302614454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK7095","BK4080","BK4231","00656","BK1230","ESG","ADC.AU"],"gpt_icon":0},{"id":"2582355602","title":"Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation","url":"https://stock-news.laohu8.com/highlight/detail?id=2582355602","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582355602?lang=en_us&edition=fundamental","pubTime":"2025-11-11 15:41","pubTimestamp":1762846860,"startTime":"0","endTime":"0","summary":"HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November,Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, \"At this crucial juncture today, China's pharmaceutical innovation is gaining increasing attention and recognition around the world. More than ever, we are convinced that original innovation is the only way forward for the industry, and open cooperation is the best way to accelerate innovation.\". Innovation should always be driven by unmet clinical needs. Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. As the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer , HANSIZHUANG, independently developed by Henlius, has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore, ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/guo-guangchang-fosun-strengthens-globalization-capabilities-accelerates-innovation-through-open-cooperation-302611277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4080","ADC","AI","BK4231","BK4528","ADC.AU","BK4023","BK4585","BK4588","BK7095","BK4543","00656","BK4587","BK1230"],"gpt_icon":0},{"id":"2581028481","title":"Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581028481","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581028481?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:00","pubTimestamp":1762477200,"startTime":"0","endTime":"0","summary":"HONG KONG, Nov. 7, 2025 /PRNewswire/ -- On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted \"The Asset Corporate Sustainability Leadership Awards 2025\" ceremony in Singapore. Fosun International Limited   was awarded \"The Asset Corporate Sustainability Leadership Awards 2025 – Gold Award\" and the \"Best Sustainability Team\".Coinciding with The Asset's 25th anniversary, the highly regarded \"The Asset ESG Corporate Awards\" was renamed \"The Asset Corporate Sustainability Leadership Awards\" this year, underscoring the winning companies' more comprehensive and holistic commitment to advancing sustainable development. After years of refinement in its selection process, the awards have become one of the most authoritative and influential ESG awards in the Asia-Pacific region. Fosun International received \"The Asset Corporate Sustainability Leadership Awards 2025 – Gold Award\" in recognition of its outstanding performance in areas including financial perfor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fosun-international-honored-with-gold-award-and-best-sustainability-team-at-the-asset-corporate-sustainability-leadership-awards-2025-302607142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK1230","BK7095","BK4120","BK4080","ADC","TISI","1OZmain","00656","BK4231"],"gpt_icon":0},{"id":"2580578233","title":"How Investors May Respond To InnoCare Pharma (SEHK:9969) Advancing Novel B7-H3 ADC and Next-Gen TRK Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2580578233","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580578233?lang=en_us&edition=fundamental","pubTime":"2025-11-02 22:23","pubTimestamp":1762093397,"startTime":"0","endTime":"0","summary":"InnoCare Pharma recently announced two key milestones: the first patient was dosed in the clinical trial of their novel B7-H3 targeted antibody-drug conjugate (ADC) ICP-B794 in China, and positive phase I/II trial data for their next-generation pan-TRK inhibitor zurletrectinib in pediatric and adolescent patients were presented at the 2025 Congress of International Society of Paediatric Oncology.\nAn important insight is that ICP-B794 targets a tumor-specific protein not yet addressed by any...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/how-investors-may-respond-to-innocare-pharma-sehk9969-advanc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/how-investors-may-respond-to-innocare-pharma-sehk9969-advanc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4231","BK1574","BK4588","09969","GEN","ISBC","BK1161","BK4585","LU2286300806.USD","BK7095","ADC","BK4211","BK4097","ADC.AU","BK4080"],"gpt_icon":0},{"id":"2579521551","title":"LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2579521551","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579521551?lang=en_us&edition=fundamental","pubTime":"2025-10-30 09:15","pubTimestamp":1761786900,"startTime":"0","endTime":"0","summary":"Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate  market.Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS' bioconjugation and drug-substance manufacturing.By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector.They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possess advanced manufacturing infrastructures in both the U.S. and Europe.James Park, CEO of LOTTE BIOLOGICS, stated, \"This collaboration marks a ","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2808960/Fig_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2808960/Fig_1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lotte-biologics-and-sk-pharmteco-sign-strategic-partnership-to-strengthen-global-adc-cdmo-capabilities-302599154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK4139","ADC","CDMO","BK4535","BK4503","BK4231","BK4551","BK7103","BK4023","BK7095","API.AU","BK4080","API"],"gpt_icon":0},{"id":"2578667189","title":"Agree Realty (ADC): Examining Valuation After Recent 5% Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2578667189","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578667189?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:30","pubTimestamp":1761658247,"startTime":"0","endTime":"0","summary":"Agree Realty (ADC) has seen its stock price gain nearly 5% over the past month, which has sparked some conversation about the factors supporting its recent momentum. Investors are taking a closer look at its performance and what is driving the interest.\nSee our latest analysis for Agree Realty.\nAgree Realty’s 1-month share price return of over 5% marks a meaningful rebound, hinting at renewed optimism after a steady but more modest pace earlier in the year. With a 1-year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-examining-valuation-after-recent-5-share-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/agree-realty-adc-examining-valuation-after-recent-5-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC.AU","BK4231","BK4080","ADC","BK7095"],"gpt_icon":0},{"id":"2577200392","title":"Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC","url":"https://stock-news.laohu8.com/highlight/detail?id=2577200392","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577200392?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:39","pubTimestamp":1761147540,"startTime":"0","endTime":"0","summary":"BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate  milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China.iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated . In recent years, China's dynamic pharmaceutical ecosystem has rapidly emerged as one of the world's leading sources of novel drug molecules. Such collaborations, however, often come with uncertainties in both China and the U.S. Following the $800 million upfront payment received in early 2024, Biokin's partnership with BMS has advanced smoothly once again. This progress has prompted skeptics to rec","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2802851/1202900558.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2802851/1202900558.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/largest-milestone-payment-secured-biokin-a-rising-chinese-pharmaceutical-mnc-302591684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4143","BK4080","ARC.AU","BK7062","ARC","BK4231","ADC.AU","ADC","BK7095"],"gpt_icon":0},{"id":"2577905335","title":"Biokin Pharmaceutical Gets Nod to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2577905335","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577905335?lang=en_us&edition=fundamental","pubTime":"2025-10-22 11:37","pubTimestamp":1761104275,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  received the approval of China's National Medical Products Administration to conduct clinical trials on injection BL-M24D1 , according to a Shanghai bourse filing on Wednesday.The drug will be tested as a treatment for patients with relapsed or refractory hematologic malignancies and advanced solid tumors.The company's shares slipped less than 2% during morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK4231","688506","ADC","BK4080","ADC.AU","BK0239"],"gpt_icon":0},{"id":"2576834179","title":"The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2576834179","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576834179?lang=en_us&edition=fundamental","pubTime":"2025-10-20 17:06","pubTimestamp":1760951160,"startTime":"0","endTime":"0","summary":"After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group .OS was significantly longer with sac-TMT than with chemotherapy ; 18-month OS rate was 65.8% and 48.0%, respectively. In the supplementary analysis, in which data were censored at the start date of subsequent ADC, the HR was 0.56 .Sac-TMT was associated with a higher incidence of stomatitis with most cases being mild and with grade 3 or higher cases reported in very few patients . Low incidence of ocular-surface toxic effects, no ILD or pneumonitis, and one infusion-related reaction  was reported in the sac-TMT group.Based on the positive results of the OptiTROP-Lung04 study, sac-TMT has been approved by the National Medical Products Administration  in China for the treatment of adult patie","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/the-new-england-journal-of-medicine-publishes-results-of-phase-iii-optitrop-lung04-study-of-sacituzumab-tirumotecan-in-advanced-egfr-tki-resistant-nsclc-302588860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","LU1941712264.USD","LU1093756325.SGD","CI","LU1069347547.HKD","BK4080","IE000M9KFDE8.USD","LU1064130708.USD","BK4534","IE00B4R5TH58.HKD","LU2324357040.USD","LU1699723380.USD","LU1116320737.USD","BK4203","LU0106261612.USD","LU0965509101.SGD","LU2308191902.HKD","MSD","OS","PFS","BK4134","LU0320765489.SGD","DAR","LU1941712348.USD","LU1162221912.USD","SG9999014542.SGD","BC","ADC.AU","LU0265550359.USD","LU0861579265.USD","BK4007","LU0965508806.USD","HR","LU1979443071.USD","LU1037948897.HKD","LU1291159041.SGD","LU0203347892.USD","LU1023059063.AUD","LU1934453819.USD","III","LU2461242641.AUD","MRK","LU2380233275.USD","BK4097","BK0239","BK4559","ADC","LU1059921491.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2576886479","title":"Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=2576886479","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576886479?lang=en_us&edition=fundamental","pubTime":"2025-10-20 10:36","pubTimestamp":1760927760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer  following progression on epidermal growth factor receptor-tyrosine kinase inhibitors  was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center  and were simultaneously published in the New England Journal of Medicine .","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2800040/image_5028780_3258648.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2800040/image_5028780_3258648.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/positive-results-from-phase-3-optitrop-lung04-trial-of-sacituzumab-tirumotecan-presented-at-esmo-presidential-symposium-and-simultaneously-published-in-nejm-302588507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","BK7095","ADC","ADC.AU"],"gpt_icon":0},{"id":"2576078264","title":"Will Agree Realty's (ADC) Dividend Hike Reveal the Strength of Its Shareholder Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576078264","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576078264?lang=en_us&edition=fundamental","pubTime":"2025-10-19 15:24","pubTimestamp":1760858653,"startTime":"0","endTime":"0","summary":"Earlier this month, Agree Realty Corporation announced a 2.3% increase in its monthly cash dividend to US$0.262 per share, with an annualized amount of US$3.144, alongside updated investment and earnings guidance for 2025.\nThis dividend hike highlights the company’s ongoing commitment to shareholder returns, reinforcing its position as a consistent dividend-growth REIT despite challenging market conditions.\nWe’ll explore how this latest dividend increase bolsters Agree Realty’s investment...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/will-agree-realtys-adc-dividend-hike-reveal-the-strength-of","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/will-agree-realtys-adc-dividend-hike-reveal-the-strength-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC.AU","BK4080","BK7095","BK4231","ADC"],"gpt_icon":0},{"id":"2576102255","title":"Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576102255","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576102255?lang=en_us&edition=fundamental","pubTime":"2025-10-19 15:00","pubTimestamp":1760857200,"startTime":"0","endTime":"0","summary":"AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design. AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs. Promising antitumor activity was observed in heavily pretreated patients with melanoma and gynecologic cancers without MUC18 preselection. SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter dose escalation and expansion study evaluating AMT-253, a MUC18-directed antibody-drug-conjugate , in patients with melanoma and other advanced solid tumors. The data are being presented on October 19th at the 2025 European Society for Medical Oncology  Annual Meeting being held in Berlin, Germany.\"We are excited by the durable antitumor activity observed in the early clinical results of AMT-253, part","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK7095","LU1093756325.SGD","IE00BYQQ9H92.USD","BK4585","BK4581","LU1721428933.USD","LENZ","BK4548","BK4084","ORR","MTD","BK4567","BK4231","LU2413666699.HKD","BK4139","BK4080","BK4554","LU0347712357.USD","LU1093756168.USD","BK4539","LU2413666426.HKD","ORR.AU","IE00BFXG0V08.USD","BK4534","BK4007","BK4588","ADC.AU","BK4219","BK4533","LU2211817866.USD","ADC","AMT"],"gpt_icon":0},{"id":"2576030917","title":"Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC","url":"https://stock-news.laohu8.com/highlight/detail?id=2576030917","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576030917?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:22","pubTimestamp":1760703720,"startTime":"0","endTime":"0","summary":"The approval is based on a multi-center, randomized, open-label, controlled, Phase 3KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients with HER2-positive unresectable or metastatic BC who have received prior trastuzumab and taxane-containing regimens. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival  as assessed by the blinded independent central review  compared with T-DM1; the beneficial trend for overall survival  of trastuzumab botidotin was also observed.Results from this study will be presented as an oral report at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany .The Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously rece","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotechs-core-product-trastuzumab-botidotin-approved-for-marketing-by-nmpa-for-her2-positive-bc-302587568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4097","LU1979443071.USD","LU1721429402.USD","BK4189","ADC.AU","BK4190","LU0012050646.USD","BC","LU1934453819.USD","LU2380233275.USD","DAR","BK4231","LU0256331488.USD","BK0060","BK4080","LU2211817866.USD","LU1064130708.USD","BK4195","LU2148510915.USD","002422","LU0106261612.USD","BK0239","OS","BK7095","PFS","LU1064131003.USD","BK4211","LU2308191902.HKD","LU1721429741.USD"],"gpt_icon":0},{"id":"2572635402","title":"Will Agree Realty’s (ADC) $1.5 Billion Investment Deepen Its Role as a Reliable Dividend Payer?","url":"https://stock-news.laohu8.com/highlight/detail?id=2572635402","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572635402?lang=en_us&edition=fundamental","pubTime":"2025-10-04 02:22","pubTimestamp":1759515777,"startTime":"0","endTime":"0","summary":"Agree Realty Corporation (NYSE: ADC) recently announced it will release its third quarter 2025 operating results after the market closes on October 21, 2025, followed by a conference call for investors on October 22, 2025.\nIn addition, the company's plans to invest around US$1.5 billion in new properties this year highlight its continued focus on expanding its portfolio of essential retail assets.\nWe'll explore how Agree Realty's large-scale investment in essential retail properties could...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice2-main-header/1585186602415"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/will-agree-realtys-adc-15-billion-investment-deepen-its-role","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/real-estate/nyse-adc/agree-realty/news/will-agree-realtys-adc-15-billion-investment-deepen-its-role","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC.AU","BK4080","BK4231","ADC","BK7095"],"gpt_icon":0},{"id":"2570246853","title":"Prabowo Arrives in Amsterdam, Rides Dutch Royal Family's Limousine","url":"https://stock-news.laohu8.com/highlight/detail?id=2570246853","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570246853?lang=en_us&edition=fundamental","pubTime":"2025-09-26 15:00","pubTimestamp":1758870034,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -Indonesian President Prabowo Subianto arrived at Schiphol International Airport, Amsterdam, the Netherlands, on Thursday, September 25, 2025, after attending the United Nations General Assembly and a visit to Canada.The head of state's entourage arrived around 09:45 local time. Prabowo is expected to receive an official welcome from Dutch King Willem-Alexander at the Huis ten Bosch Palace.Upon arrival at Schipol Airport, President Prabowo was welcomed by the Aide-de-Camp  of the Dutch King, Lieutenant Colonel Jol Postma, the Head of Visits and Events of the Protocol and House Country Department, Dutch Minister of Foreign Affairs Bob Aal, Indonesian Ambassador to the Kingdom of the Netherlands Mayerfas, and Defense Attach of the Indonesian Embassy in The Hague, Navy Colonel  Rikrik Permadi Sobana.","market":"fut","thumbnail":"https://statik.tempo.co/data/2025/09/26/id_1430743/1430743_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/09/26/id_1430743/1430743_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2052129/prabowo-arrives-in-amsterdam-rides-dutch-royal-familys-limousine","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2052129/prabowo-arrives-in-amsterdam-rides-dutch-royal-familys-limousine","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4231","BK7056","ADC.AU","BK4585","BK4588","BCC","BK4104","LU0345780281.USD","RGLD","BK7095","LU0345780521.USD","ADC","BK4080","BCC.AU","BK4017","BK4567"],"gpt_icon":0},{"id":"2569795692","title":"Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2569795692","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569795692?lang=en_us&edition=fundamental","pubTime":"2025-09-23 17:03","pubTimestamp":1758618180,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Sept. 23, 2025 /PRNewswire/ --The 2025 European Society for Medical Oncology  Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan , HER2 ADC A166 , and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts  and presented as oral reports, including one featured in the Presidential Symposium; one Phase III clinical study of A166 was selected for LBA and presented as oral report.Abstract titles of these studies have been published on the official website of ESMO. The study results to be presented include:. Title:Sacituzumab tirumotecan  in Participants  with Previously Treated, Advanced KRAS-Mutant NSCLC: Results from Cohort 5d of the SKB264-II-08 StudyPresentation Type: PosterPresentation #: 1945PDate and Ses","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-to-present-results-from-multiple-clinical-studies-at-the-2025-esmo-congress-302564241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","LU1934455863.HKD","LU1983299246.USD","LU1989772923.USD","BK4534","CDE","LU0265550359.USD","LU0098860793.USD","LU2308191902.HKD","BC","LU1116320901.HKD","IE0002141913.USD","DAR","MRK","PFS","LU1571399168.USD","LU1066053197.SGD","LU1430594728.SGD","LU0211331839.USD","LU0106261372.USD","LU1037948541.HKD","MSD","002422","BK4195","LU2023250843.SGD","ADC.AU","LU1974910355.USD","SG9999001176.SGD","LU1162221912.USD","LU1979443071.USD","LU2461242641.AUD","BK4190","LU0265550946.USD","LU1941712264.USD","LU1929549753.HKD","ADC","CDE.AU","LU0320765646.SGD","BK4189","LU0320765489.SGD","LU1223082196.USD","IE00B1BXHZ80.USD","LU1069347547.HKD","IE00B2B36J28.USD","BLZ.SI","LU0203345920.USD","LU1223082519.USD","EC","IE00B4R5TH58.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}